B tier · viable
Dapoxetine has a genuine randomised evidence base — a meta-analysis of 6 RCTs and 5,934 patients showing statistically significant IELT prolongation — and approval across 22 EU member states plus Norway, but the effect is modest, adverse events affected half of treated patients, and it has never been approved in the United States.
dapoxetine
Dapoxetine is a short-acting selective serotonin reuptake inhibitor developed specifically for on-demand treatment of premature ejaculation in adult men. It is approved across much of Europe and many other countries but has never received FDA approval in the United States.
the explanation
Dapoxetine is an antidepressant-type drug redesigned to act and clear quickly, used for premature ejaculation. It is licensed in much of Europe but not in the United States, and side effects were common in the trials.
regulatory status
Approved in EU and many countries; NOT approved in the United States
First authorised in Sweden in February 2009 for premature ejaculation in men aged 18-64, then extended through mutual recognition to 22 EU member states and Norway. A CHMP referral concluded in 2012 that the benefits of the higher strength outweighed its risks, with the restriction that treatment cannot be initiated at that strength. The FDA has never approved dapoxetine.
how it works · proposed mechanism
Dapoxetine inhibits presynaptic serotonin reuptake, raising synaptic serotonin in pathways that regulate the ejaculatory reflex.
Serotonergic ejaculatory delay
Ejaculation is coordinated by a spinal generator under descending serotonergic inhibition. Raising synaptic serotonin increases the threshold for the ejaculatory reflex, which is the shared mechanism behind all SSRI use in premature ejaculation.
Engineered short kinetics
Unlike chronic-use SSRIs, dapoxetine is rapidly absorbed and rapidly eliminated with an initial half-life of about 1.3-1.4 hours and minimal accumulation across repeated dosing. This is what makes on-demand rather than continuous use feasible.
Autonomic and vasovagal effects
Acute serotonergic surges can trigger prodromal vasovagal responses and syncope, which is the specific safety concern that dominated the European regulatory review. This risk scaled with strength rather than being uniform across the dose range.
what’s reported
evidence shape
5 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Dapoxetine's evidence base is for premature ejaculation in diagnosed adult men, and none of it speaks to use as a general sexual performance enhancer or in combination with the PDE5 inhibitors it is often bundled with in consumer channels. It is also not an FDA-approved product in the United States, so any US-facing supply is by definition unapproved, and the syncope signal that dominated its European review is a real risk that supervised prescribing exists to manage.
key published findings
- Human trial (meta-analysis of RCTs): Li and colleagues pooled 6 randomised controlled trials with 5,934 patients and found a mean IELT difference versus placebo of 1.59 minutes (95% CI 1.30 to 1.88; P < 0.00001).
- Human trial (same meta-analysis, dose comparison): the higher strength outperformed the lower by a mean difference of -0.47 (95% CI -0.73 to -0.20; P = 0.0005) — a modest incremental gain that formed the crux of the European regulatory dispute.
- Human trial (same meta-analysis, safety): adverse events occurred in 50.5% of the dapoxetine group versus 27.9% of placebo, though severe adverse events were described as rare.
- Human trial (randomised, double-blind, placebo-controlled phase 3 across 22 countries): Buvat and colleagues enrolled 1,162 men with baseline IELT of 0.9 minutes; endpoint geometric mean IELT was 1.1 minutes on placebo versus 1.8 and 2.3 minutes on the two active strengths, but discontinuation for adverse events rose from 1.3% on placebo to 3.9% and 8.2% on active treatment.
- Regulatory (EMA referral): the CHMP concluded that the benefits of the higher-strength tablet outweigh its risks, with the European Commission confirming this on 20 January 2012, but imposed the restriction that treatment must not be initiated at that strength.
limitations of the evidence
- The pooled IELT gain of roughly 1.6 minutes is statistically robust but clinically modest, and IELT is a surrogate that correlates imperfectly with patient and partner satisfaction.
- Adverse events affected more than half of treated patients, and dropout driven by tolerability limits the durability of real-world benefit.
- The FDA has never approved dapoxetine despite its European authorisation, so the most rigorous regulator to have reviewed the file did not find the benefit-risk balance sufficient for US marketing.
documented safety signals
- Syncope and orthostatic hypotension are the defining safety concern, and were the specific issue that triggered a formal European regulatory referral over the higher strength.
- Prodromal vasovagal symptoms — dizziness, lightheadedness, sweating, nausea — may precede syncope.
- Nausea, dizziness, headache, diarrhoea and somnolence are common, contributing to a 50.5% adverse event rate versus 27.9% on placebo.
- As a serotonergic agent, dapoxetine carries serotonin syndrome risk in combination with MAO inhibitors, other SSRIs and SNRIs, triptans, tramadol, linezolid, lithium and St John's wort.
- SSRI class labelling addresses suicidal ideation and behaviour, and dapoxetine is generally contraindicated in men with a history of mania, bipolar disorder or significant depression.
- Contraindicated in significant cardiac disease including heart failure, conduction abnormalities, ischaemic heart disease and significant valvular disease, given the syncope risk.
- Contraindicated in moderate to severe hepatic impairment.
- Alcohol potentiates the neurocardiogenic adverse effects and increases syncope risk.
- Interaction with potent CYP3A4 inhibitors materially raises exposure; caution with PDE5 inhibitors given additive orthostatic effects.
- Because it is not FDA-approved, US-facing supply is unapproved and of unverified identity, purity and content.
identity
| full name | Dapoxetine hydrochloride |
| category | Sexual Health |
| modality | small molecule |
| formula | C21H23NO |
| molar mass | 305.4 g/mol |
| cas | 119356-77-3 |
| half-life | ~1.3-1.4 h (initial phase) |
laboratory handling
| storage | Marketed film-coated tablets are stored at controlled room temperature in the original packaging per the approved European product information. |
| solubility | Dapoxetine hydrochloride is the marketed salt and is water-soluble; the free base is lipophilic, consistent with its rapid absorption profile. |
| co-studied with | Documented interaction hazards rather than a regimen: contraindicated with MAO inhibitors and other serotonergic agents due to serotonin syndrome risk; contraindicated with potent CYP3A4 inhibitors; and caution is specified with PDE5 inhibitors and alcohol because of additive orthostatic hypotension and syncope. Consumer channels frequently sell dapoxetine co-formulated with sildenafil or tadalafil, a combination not covered by the approved product information. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
5 citedEuropean Medicines Agency · 2012 · official
Drugs of Today (Barcelona) · 2009 · review
Clinical Therapeutics · 2014 · randomized
European Urology · 2009 · randomized
Database of Abstracts of Reviews of Effects, NCBI Bookshelf · 2014 · randomized
others in Sexual Health